Funds and prices
Overview
Actively managed equity portfolio investing worldwide in biotech companies.
Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution.
Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide.
Investment decisions are based on a disciplined investment philosophy and fundamental research.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
The exchange rate risk between USD and EUR is not hedged.
Benefits
Easy access to the global biotech sector.
Offers investors broad diversification within the sector.
The fund taps into the knowledge of proven sector specialists.
ÃÛ¶¹ÊÓƵ's proprietary fundamental valuation approach enables the most attractive biotechnology companies to be consistently identified.
Investors benefit from a global investment platform of ÃÛ¶¹ÊÓƵ Asset Management.
Risks
Features
Product category |
ÃÛ¶¹ÊÓƵ Equity Funds
ÃÛ¶¹ÊÓƵ Sector Funds |
Product domicile |
Luxembourg
|
Portfolio management |
ÃÛ¶¹ÊÓƵ Asset Management (Americas) LLC, New York
|
Fund management |
ÃÛ¶¹ÊÓƵ Fund Management (Luxembourg) S.A., Luxembourg
|
Custodian bank |
ÃÛ¶¹ÊÓƵ Europe SE, Luxembourg Branch
|
Tax representative |
Ernst & Young Steuerberatungsgesellschaft m.b.H. Wien
|
Day of inception |
January 3, 2023
|
Currency of account |
USD
|
Currency of unit class |
EUR
|
Close of financial year |
November 30
|
Issue / redemption |
daily
|
Distribution |
Reinvestment
|
Maturity |
Open end
|
Management fee |
0.82% p.a.
|
Total expense ratio (TER) |
1.07% p.a.
|
Swing pricing |
yes
|
Minimum investment |
n.a.
|
Reference Index / Benchmark |
MSCI US Investable Market Biotechnology 10/40 Index in EUR
|
ISIN |
LU1769088235
|
Bloomberg Ticker |
ÃÛ¶¹ÊÓƵBIOQ LX
|
Performance and Prices
Percentage growth
as of April 3, 2024EUR(%) | |
YTD | |
1M | |
3M | |
6M | |
1Y | 1.53 |
2Y | |
3Y | - |
5Y | - |
ø p.a.5Y |
Current data
Net asset value | 03.04.2024 | EUR 96.34 |
High - last 12 months | 08.01.2024 | EUR 103.91 |
Low - last 12 months | 27.10.2023 | EUR 83.21 |
Assets of the unit class in mn | 03.04.2024 | EUR 0.02 |
Total product assets in mn | 03.04.2024 | EUR 439.15 |
Date
|
2 years
|
5 years
|
|
Risk Free Rate | 31.03.2024 | 2.23% | 0.61% |
Structures
Fees
Distributions
Authorisations
Literature
Document type
|
Document Language
|
|
Prospectus |
|
|
Key Information Document |
|
|
Past performance |
|
|
Previous performance scenario |
|
|
Statutes / Management regulations |
|
|
ESG Disclosure |
|
|
Document type
|
Document Language
|
|
Annual report |
|
|
SFDR Periodic Report Annex |
|
|
Semi-annual report |
|
|